Immunotherapy with stem cell transplant for relapsed Hodgkin lymphoma
Treatments studied
Part of Blood & lymphatic, Cancer, Immune system & allergy clinical trials.
This Phase 2 trial tests whether pembrolizumab plus brentuximab works better than standard chemotherapy followed by an autologous stem cell transplant for people whose classic Hodgkin lymphoma has come back or did not respond. It may help by improving cancer control before and around stem cell transplant and by comparing outcomes between the two treatment approaches.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are age 18 or older, and you have classic Hodgkin lymphoma that has relapsed or is not responding after anthracycline chemotherapy, and you are eligible for high-dose chemotherapy plus your own stem cell transplant.
- You have a measurable tumor that can be tracked on scans or exams, based on the trial’s staging rules.
- Your overall health is good enough for treatment (ECOG performance status 0–1), and you’re expected to live more than 90 days.
- Your blood counts and organ function are within allowed ranges (for example: neutrophils and platelets are high enough, and liver/kidney tests are acceptable).
- You can complete quality-of-life questionnaires in English or French, and you can attend treatment and follow-up visits.
- You have tumor tissue from your original diagnosis biopsy and (if available) another biopsy from the relapse/refractory disease, or you can provide pathology proof the study can review.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests a combination of the immunotherapy drug pembrolizumab with a chemotherapy regimen called GVD for patients whose Hodgkin's lymphoma has not responded or has returned after initial treatment. The goal is to see if this combination works better than standard approaches.
This Phase 3 trial studies whether adding brentuximab vedotin to standard chemotherapy improves outcomes for people with newly diagnosed early-stage classical Hodgkin lymphoma. It may help reduce the chance the cancer returns or improves how well treatment works.
This trial tests a new treatment where your own immune cells are modified to better attack Hodgkin lymphoma cells. It is for people whose disease has not responded to other therapies.
This trial tests whether a PD-1 inhibitor (a type of immunotherapy) given after an autologous stem cell transplant can help prevent Hodgkin lymphoma from coming back in people at high risk of relapse.
This trial tests nivolumab (an immune therapy) combined with ruxolitinib (a drug that targets immune signaling) for people whose classical Hodgkin lymphoma has come back or did not respond. It may help shrink the lymphoma and improve disease control after prior treatments, including checkpoint inhibitor therapy.
This trial tests whether adding a type of immune-boosting drug (called checkpoint inhibitor immunotherapy) after high-dose chemotherapy and stem cell transplant helps people with Hodgkin lymphoma that has returned or didn't respond to initial treatment. The goal is to see if this combination works better than chemotherapy and transplant alone.
Hear when a new Hodgkin Lymphoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.